B
AI platform for discovering new medicines and transforming the drug development process.
About
BenevolentAI is a clinical-stage AI drug discovery company that uses its proprietary platform to uncover new biology, predict novel targets, and develop first-in-class or best-in-class drugs for complex diseases. They combine AI with scientific expertise and wet-lab facilities to accelerate the drug discovery and development process, aiming to reduce costs, failure rates, and time to market.
Tags
Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does BenevolentAI do?
BenevolentAI is a clinical-stage AI drug discovery company that uses its proprietary platform to uncover new biology, predict novel targets, and develop first-in-class or best-in-class drugs for complex diseases. They combine AI with scientific expertise and wet-lab facilities to accelerate the drug discovery and development process, aiming to reduce costs, failure rates, and time to market.
How much funding has BenevolentAI raised?
BenevolentAI has raised a total of $205M in funding. The most recent round on record is Series C.
Where is BenevolentAI headquartered?
BenevolentAI is headquartered in London, United Kingdom.
When was BenevolentAI founded?
BenevolentAI was founded in 2013.
What industry does BenevolentAI operate in?
BenevolentAI operates in Drug Discovery AI, AI Drug Discovery, Biotech, HealthTech, Drug Discovery, Clinical Trials.
What is BenevolentAI's current status?
BenevolentAI's current operating status is: Acquired.